Skip to main content
Top
Published in: International Urology and Nephrology 6/2019

01-06-2019 | Nephrectomy | Urology - Original Paper

Do renal cell carcinoma patients with brain metastases still need nephrectomy?

Authors: Wei Zhuang, Yining Li, Panyu Chen, Jialiang Wang, Weihui Liu, Jiabi Chen

Published in: International Urology and Nephrology | Issue 6/2019

Login to get access

Abstract

Purpose

To evaluate the value of nephrectomy for survival prognosis in renal cell carcinoma (RCC) patients with brain metastases (BM).

Methods

There were 933 RCC patients diagnosed with BM in SEER database from 2010 to 2014. Kaplan–Meier method and Cox regression model were used to analyze the survival prognosis. The effect of nephrectomy on overall survival (OS) was analyzed by propensity score matching. The competitive risk model was performed to explore the relationship between surgery and cancer-specific survival (CSS), and the nomogram visualization model was established by R language to predict survival rate.

Results

BM accounted for 1.5% of newly diagnosed RCC patients and 11.1% of M1 stage patients with the median survival time of 5 months (95% CI 4.5–5.5). Age 45–65 years, tumor diameter > 10 cm and histologic type of clear cell renal cell carcinoma (ccRCC) were high risk factors for BM in RCC patients. Age, N stage, lung metastasis and nephrectomy were independent prognostic factors. Nephrectomy was beneficial for both OS and CSS for the analysis of 216 patients successfully matched. The nomogram model has a certain value in predicting the survival rate with the internal verification c-index of 0.727.

Conclusions

Patients with high risk of BM (age 45–65 years, tumor diameter > 10 cm, histologic type of ccRCC) should emphasize brain imaging screening during follow-up. Nephrectomy may bring survival advantages for RCC patients with BM. Nomogram model based on nephrectomy can helps predicting the 1-, 2- and 3-year survival rates.
Literature
1.
go back to reference Cagney DN, Martin AM, Catalano PJ et al (2017) Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 19:1511–1521CrossRefPubMedPubMedCentral Cagney DN, Martin AM, Catalano PJ et al (2017) Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 19:1511–1521CrossRefPubMedPubMedCentral
2.
go back to reference Davis FG, Dolecek TA, McCarthy BJ et al (2012) Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol 14:1171–1177CrossRefPubMedPubMedCentral Davis FG, Dolecek TA, McCarthy BJ et al (2012) Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol 14:1171–1177CrossRefPubMedPubMedCentral
3.
go back to reference Sun M, De Velasco G, Brastianos PK et al (2018) The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort. Eur Urol Focus 428:1–8 Sun M, De Velasco G, Brastianos PK et al (2018) The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort. Eur Urol Focus 428:1–8
4.
go back to reference Patil S, Manola J, Elson P et al (2012) Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol 188:2095–2100CrossRefPubMed Patil S, Manola J, Elson P et al (2012) Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol 188:2095–2100CrossRefPubMed
5.
go back to reference Heng DY, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148CrossRefPubMedPubMedCentral Heng DY, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148CrossRefPubMedPubMedCentral
6.
7.
go back to reference Hellenthal NJ, Mansour AM, Hayn MH et al (2013) Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma. Urol Oncol 31:36–41CrossRefPubMed Hellenthal NJ, Mansour AM, Hayn MH et al (2013) Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma. Urol Oncol 31:36–41CrossRefPubMed
8.
go back to reference Xiao WJ, Zhu Y, Dai B et al (2015) Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis. Int Braz J Urol 41:288–295CrossRefPubMedPubMedCentral Xiao WJ, Zhu Y, Dai B et al (2015) Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis. Int Braz J Urol 41:288–295CrossRefPubMedPubMedCentral
9.
go back to reference Iasonos A, Schrag D, Raj GV et al (2008) How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26:1364–1370CrossRefPubMed Iasonos A, Schrag D, Raj GV et al (2008) How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26:1364–1370CrossRefPubMed
10.
go back to reference Huang F, Du C, Sun M et al (2015) Propensity score matching in SPSS. Nan Fang Yi Ke Da Xue Xue Bao 35:1597–1601PubMed Huang F, Du C, Sun M et al (2015) Propensity score matching in SPSS. Nan Fang Yi Ke Da Xue Xue Bao 35:1597–1601PubMed
11.
go back to reference Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40:381–387CrossRefPubMed Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40:381–387CrossRefPubMed
12.
go back to reference Remon J, Lianes P, Martínez S (2012) Brain metastases from renal cell carcinoma. Should we change the current standard. Cancer Treat Rev 38:249–257CrossRefPubMed Remon J, Lianes P, Martínez S (2012) Brain metastases from renal cell carcinoma. Should we change the current standard. Cancer Treat Rev 38:249–257CrossRefPubMed
13.
go back to reference Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 77:655–661CrossRefPubMed Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 77:655–661CrossRefPubMed
14.
go back to reference Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500CrossRefPubMed Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500CrossRefPubMed
15.
go back to reference Vecht CJ, Haaxma-Reiche H, Noordijk EM et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery. Ann Neurol 33:583–590CrossRefPubMed Vecht CJ, Haaxma-Reiche H, Noordijk EM et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery. Ann Neurol 33:583–590CrossRefPubMed
16.
go back to reference Tonyali S, Yazici S (2016) Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies. Int Urol Nephrol 48:671–680CrossRefPubMed Tonyali S, Yazici S (2016) Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies. Int Urol Nephrol 48:671–680CrossRefPubMed
17.
go back to reference Meyer CP, Sun M, Karam JA et al (2017) Complications after metastasectomy for renal cell carcinoma-a population-based assessment. Eur Urol 72:171–174CrossRefPubMed Meyer CP, Sun M, Karam JA et al (2017) Complications after metastasectomy for renal cell carcinoma-a population-based assessment. Eur Urol 72:171–174CrossRefPubMed
18.
go back to reference Mintz AH, Kestle J, Rathbone MP et al (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78:1470–1476CrossRefPubMed Mintz AH, Kestle J, Rathbone MP et al (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78:1470–1476CrossRefPubMed
19.
go back to reference Capitanio U, Zini L, Perrotte P et al (2008) Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology 72:1090–1095CrossRefPubMed Capitanio U, Zini L, Perrotte P et al (2008) Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology 72:1090–1095CrossRefPubMed
20.
go back to reference Dreicer R, Galbraith SS, Davis CS et al (1997) Surgical resection of metastatic renal cell carcinoma: the University of Iowa experience. Urol Oncol 3:99–101CrossRefPubMed Dreicer R, Galbraith SS, Davis CS et al (1997) Surgical resection of metastatic renal cell carcinoma: the University of Iowa experience. Urol Oncol 3:99–101CrossRefPubMed
21.
go back to reference Culp SH, Karam JA, Wood CG (2014) Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol 32:561–568CrossRefPubMed Culp SH, Karam JA, Wood CG (2014) Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol 32:561–568CrossRefPubMed
22.
go back to reference Karakiewicz PI, Suardi N, Capitanio U et al (2009) A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 55:287–295CrossRefPubMed Karakiewicz PI, Suardi N, Capitanio U et al (2009) A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 55:287–295CrossRefPubMed
23.
go back to reference Koo KC, Lee KS, Cho KS et al (2016) Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio. Int Urol Nephrol 48:985–992CrossRefPubMed Koo KC, Lee KS, Cho KS et al (2016) Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio. Int Urol Nephrol 48:985–992CrossRefPubMed
Metadata
Title
Do renal cell carcinoma patients with brain metastases still need nephrectomy?
Authors
Wei Zhuang
Yining Li
Panyu Chen
Jialiang Wang
Weihui Liu
Jiabi Chen
Publication date
01-06-2019
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02139-9

Other articles of this Issue 6/2019

International Urology and Nephrology 6/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.